Drugs / KR230109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07345390 | Jan → Oct 2026 expected | acne | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KR230109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07345390 ↗ |
| Known as | KR230109 cream | “KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients” NCT07345390 ↗ |
| Route | Topical | “KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients” NCT07345390 ↗ |